pocketful logo light
pocketful logo light
Hindustan Bio Sciences Ltd logo

Hindustan Bio Sciences Ltd

NSE: BSE: 532041

8.70

(1.75%)

Sat, 30 May 2026, 00:20 pm

Hindustan Bio Sciences Share Price Live Chart

1 Day

(1.75%)

No Result Found

Summary

  • Market Cap

    8.71

  • Net Profit

    0.10

  • P/B

    7.93

  • Sector P/E

    45.42

  • P/E

    69.80

  • EV/EBITDA

    96.60

  • Debt/Equity (Industry)

    0.52

  • Interest Cover (Industry)

    40.83

  • ROCE (Industry)

    0.01

  • RONW (Industry)

    0.01

  • ROE

    4.88

  • ROCE

    2.18

  • Debt/Equity

    2.98

  • EPS (TTM)

    0.14

  • Dividend Yield

    0

  • Book Value

    0.84

  • Interest Cover

    0

Analysis

all

thumbs up icon

Pros

  • Hindustan Bio Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Hindustan Bio Sciences is profitable, therefore cash runway is not a concern.
  • Hindustan Bio Sciences is profitable, therefore cash runway is not a concern.
  • Interest payments on debt are well covered by earnings (EBIT is 195.2x coverage).
  • Low level of unsold assets.
thumbs up icon

Cons

  • Unable to evaluate Hindustan Bio Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Hindustan Bio Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Operating cash flow is negative therefore debt is not well covered.
  • Debt is not covered by short term assets, assets are 0.5x debt.
  • Hindustan Bio Sciences's long term commitments exceed its cash and other short term assets.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters12.1912.1912.1912.1912.19
FII00000
DII00000
Public87.8187.8187.8187.8187.81
Government00000

Read More

Technical Analysis

RSI

45.19

MACD

-0.07

50 DMA

8.62

200 DMA

7.63

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic13.0910.979.898.857.776.734.61
Fibonacci10.9710.169.668.858.047.546.73
Camarilla9.409.219.018.858.638.438.24

Pivots Level: Classic

R3

+4.24

13.09

R2

+2.12

10.97

R1

+1.05

9.89

8.85
8.85
Pivot Point
LTP: 8.50

S1

-1.07

7.77

S2

-2.12

6.73

S3

-4.24

4.61

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    8.68

  • 20-EMA

    8.77

  • 30-EMA

    8.76

  • 50-EMA

    8.59

  • 100-EMA

    8.18

  • 200-EMA

    8.00

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
30 May 2026board-meetingsAccounts, Quarterly Results
31 Jan 2026board-meetingsQuarterly Results
31 Oct 2025board-meetingsQuarterly Results
31 Jul 2025agm
31 Jul 2024agm
04 Dec 2023egm
31 Jul 2023agm
07 Sept 2022agm
18 Jun 2021agm

Read More

Peer Comparison

Hindustan Bio Sciences Ltd logo

Hindustan Bio Sciences Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Read More

Hindustan Bio Sciences Ltd About

Hindustan Bio Sciences is engaged in the manufacturing and sale of pharmaceutical products.

Industry

Trading

Founded

1991

Headquarters

CEO

J.V.R. Mohan Raju

Employees

Contact

Website icon

Website

http://www.hindustanbiosciences.in

Email icon

Email

mohan.hindustanbio@gmail.com, pharma.hindustanbio@

Phone icon

Phone

91-40-23555161/23555181

Location icon

Location

H No 8-2-269/S PlotNo 31 RdNo2, Sagar Co-Op Hous Banjara Hills, Hyderabad, Telangana, 500034

Read More

Hindustan Bio Sciences Ltd Company History

YearHistory
2001
  • The Company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd for dematerialisation.
2004
  • Hindustan Bio bagged GEAC nod for recombinant human erythropoietin.
2005
  • Hindustan Bio Sciences Ltd received an order for Antiretroviral drug for a value of Rs 269.30 million from China.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
RATNESH YOGESH BHONSLEbulkSell535016.5727 Oct 2025
VANDANA YOGESH BHOSALEbulkSell1065187.2923 Oct 2025
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDbulkBuy790213.4723 Oct 2024
VIVEK KANDAbulkBuy5250013.4623 Oct 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDbulkSell8400013.4623 Oct 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDbulkBuy5360111.0917 Oct 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDbulkBuy6500013.7820 Oct 2023
JAI VINAYAK SECURITIESbulkBuy5368012.4818 Oct 2023
JAI VINAYAK SECURITIESbulkSell5368012.3718 Oct 2023
JAI VINAYAK SECURITIESbulkSell5595211.0517 Oct 2023

Read More

Hindustan Bio Sciences Ltd News

Hindustan Bio Sciences Compliance Report

Hindustan Bio Sciences filed its Annual Secretarial Compliance Report for FY26. The report confirms full adherence to SEBI LODR regulations.

21 May 2026

companies

Board Meeting on May 30

Hindustan Bio Sciences Limited board meets on May 30, 2026, to consider audited financial results for FY26.

19 May 2026

companies

Hindustan Bio Sciences Q4 FY26 Demat Certificate

Hindustan Bio Sciences Limited confirms no equity shares received for dematerialization during Q4 FY26 period from January to March 2026, as per SEBI regulatory compliance.

14 Apr 2026

companies

Hindustan Bio Sciences Q3FY26 Profit Jumps

Hindustan Bio Sciences Limited reported a profit of ₹8.20 lakhs for Q3FY26 ended December 31, 2025, marking a strong turnaround from losses in previous quarters.

31 Jan 2026

co actions results

Hindustan Bio Sciences Reports Share Acquisition

Bosco Armando Menezes & Emily Bosco Menezes acquire 15,000 shares through open market purchase, increasing combined holding to 5.12% in Hindustan Bio Sciences Limited.

23 Jan 2026

co actions results

Read More